A Phase I Dose Finding Study of MB-CART2219.1

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
LymphomaCLLAcute Lymphoblastic Leukemia, Pediatric
Interventions
BIOLOGICAL

CAR-T cells targeting CD19 and CD22

"Using the 3+3 design, the following dose levels will be assessed:~Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg"

Trial Locations (2)

72076

RECRUITING

University Hospital , Department of Internal Medicine II, Tübingen

NOT_YET_RECRUITING

University Hospital, Clinic for Pediatric Medicine, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER